GraniteShares 2x Long COIN Daily ETF vs CVS Health Corp — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.04 (market cap $534.51M), while CVS Health Corp trades at $86.3 (market cap $112.49B). The key difference: CVS Health Corp is far larger — about 210.5× GraniteShares 2x Long COIN Daily ETF's market cap, and CVS Health Corp pays a 3.02% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and CVS Health Corp for 83 Days on average.
| CONL | CVS | |
|---|---|---|
Market Cap | $534.51M | $112.49B |
Volume | 15,212,221 | 8,467,392 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $110.60 |
52-Week Low | $3.93 | $70.08 |
Typical Hold Time | 15 Days | 83 Days |
Enterprise Value | — | $174.83B |
Dividend Yield | — | 3.02% |
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) is trading at $5.23, down 7.76% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, making it highly volatile. Recent news highlights significant price gaps and performance volatility, with one article noting an 85% decline when Coinbase fell 50%.
The outlook remains high-risk due to leveraged exposure to Coinbase volatility. Investment opportunity exists for speculative traders betting on Coinbase rebounds, but risks include amplified losses, tracking error, and crypto market sentiment swings. Caution is warranted given the bearish technical setup and leveraged structure.
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →